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Perampanel is approved for adjunctive therapy of focal epilepsy with
or without secondarily generalized seizures in patients aged >12 years.
This narrative review uses real-world and clinical trial data to
elucidate perampanel’s role in the clinic. Audit data show good
tolerability with perampanel and higher freedom-from-seizure rates in
elderly vs younger patients. When using perampanel in elderly
patients, special attention should be given to comorbidities and co-
medication to avoid potential interactions or adverse events. Slower
titration is generally recommended, and seizure control should be
reassessed at a dose of 4 mg before further dose increases. Perampanel
efficacy is similar in adolescents and adults; however, somnolence,
nasopharyngitis, and aggression are more frequent in adolescents vs
the overall population. Individualized and slow-dose titration can
minimize adverse events. Low serum concentrations of perampanel
may occur in patients also receiving some enzyme-inducing anti-
epileptic drugs; a perampanel dose increase may be required. Adverse
events of importance with perampanel include dizziness; anger,
aggression, and hostile behavior (particularly in adolescents); and falls
(particularly in patients >65 years). An individualized approach to
dosing, including slower up-titration and bedtime dosing, reduces
dizziness risk. Other drugs may cause or aggravate dizziness; reducing
concomitant drugs may be necessary when up-titrating perampanel. It
would seem clinically appropriate to give due consideration to
avoiding use in patients with a history of anger or hostile/aggressive
behavior. The possibility of such behaviors should be discussed with
patients before starting perampanel, with monitoring during up-
titration. Slower up-titration of perampanel in older patients helps
reduce fall risk.
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Introduction
Importance of real-world data
The armamentarium of anti-epileptic drugs
(AEDs) has increased exponentially over the past
20 years, with the introduction of 15 new com-
pounds (1). However, despite the plethora of
novel agents for the adjunctive treatment of
uncontrolled focal seizures, this common type of
seizure remains uncontrolled in more than 30%
of patients (2). Furthermore, resistance to AEDs
makes it improbable that a single agent could
eradicate refractory epilepsy, increasing the role
of combination therapy. However, there is a
higher risk of neurotoxicity with polytherapy
using drugs that have a similar mechanism of
action (3). Thus, AEDs with novel mechanisms
of action offer an opportunity to improve both
seizure control and treatment tolerability (1).
Such AEDs may also allow for better individual-
ization of treatment to patient characteristics,
such as age, sex, side effects, comorbidities, and
the potential for drug–drug interactions (1–4).
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It is important for clinicians to understand
how these AEDs might be best used in real-world
clinical settings. However, clinical trials of AEDs,
which are required for regulatory purposes, often
do not reflect drug use in everyday clinical prac-
tice (5, 6). For example, they are based on fixed
doses compared with placebo in patients using up
to three AEDs, the dosage range tends to be
higher, and the titration schedule is often more
rapid than in clinical practice (7). Furthermore,
tolerability data generated in clinical trials may
overestimate drug toxicity in less severely affected
patients taking fewer AEDs (8). Thus, there is a
need for real-world data that reflect the use of
AEDs in everyday clinical practice to supplement
the clinical trial data (9).
Real-world data often come from observational
studies; that is, studies in which participants are
not randomized or otherwise pre-assigned to a
treatment, but rather the choice of treatment is
decided upon by physicians (often in consultation
with patients) (9). In a prospective observational
study, outcomes of interest are studied after the
study commences and the patient is exposed to
the interventions, whereas in a retrospective
observational study existing secondary data
sources in which both exposure and outcomes
have already occurred are used (9). Retrospective
studies have the advantages of low cost and fast
execution; however, the datasets used may not
contain all the information required. Prospective
observational studies offer the potential for a
fuller dataset (although this may not be as com-
plete as in a randomized controlled trial), but are
more costly and slower than retrospective studies.
Ultimately, the choice of design will depend on
the question being asked, but will also involve
trade-offs between speed and cost, and the
quality and relevance of data collected (9).
Perampanel clinical profile
Perampanel is a selective non-competitive AMPA
(a-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid) receptor antagonist used as adjunctive
therapy for focal seizures with or without secon-
darily generalized seizures in patients >12 years
with epilepsy. The efficacy and tolerability of per-
ampanel has been evaluated in an extensive clini-
cal trial program, which included three
randomized, double-blind, placebo-controlled
phase 3 studies in patients experiencing focal sei-
zures despite treatment with up to three AEDs
(E2007-304, -305, -306) and one extension study
(E2007-307) (10–13). In the first three trials,
patients were randomized to an initial daily dose
of perampanel 2, 4, 8, or 12 mg or placebo for
19 weeks in the ‘core’ phase; subsequently, the
perampanel dose could be titrated upwards to a
tolerable level. At the conclusion of the core
phase, participants were eligible to participate in
an open-label extension phase, during which
those randomized to perampanel continued on
their core dosage, while those randomized to pla-
cebo were given perampanel at a 2 mg initial
daily dose, titrated upwards to a tolerable dose
over 19 weeks. In total, 1218 patients entered the
open-label maintenance period (planned duration
5 years).
In all placebo-controlled studies, perampanel 4,
8, and 12 mg/day consistently and significantly
reduced the frequency of focal seizures compared
with placebo. Responder rates and freedom-from-
seizure rates were also improved (10–12). A post
hoc analysis of pooled data from 1480 patients in
these randomized trials supported the individual
study data (14). During up to 3 years’ follow-up
in the open-label extension study, seizure
responses remained stable, with marked reduc-
tions, particularly in secondarily generalized
seizures (13).
Perampanel was associated with a predictable
and acceptable adverse-event profile, with most
adverse events being mild or moderate in inten-
sity (10–12, 15). The most common adverse
events with perampanel occurred in the central
nervous system [dizziness (10.0–47.9%) and som-
nolence (9.3–18.2%)] and were dose dependent.
Headache, fall, irritability, ataxia, and fatigue
also occurred in ≥10% of patients in any treat-
ment group. Aggression, ataxia, blurred vision,
convulsion, dizziness, dysarthria, fatigue, head-
ache, hypersomnia, somnolence, and vertigo most
frequently resulted in the discontinuation, reduc-
tion, or interruption of perampanel dosing. There
were no drug-related serious adverse events and
no cases of sudden unexpected death in epilepsy.
The adverse-event profile with long-term use of
perampanel reflected that seen in placebo-
controlled trials (13).
Perampanel has also been evaluated in real-
world clinical settings. Here we use real-world
cohort data, supplemented with clinical trial data,
to further elucidate the role of perampanel in the
clinic, providing practical insights into optimizing
perampanel use, including managing common
side effects, key considerations for add-on use
with other AEDs, and the use of perampanel in
specific patient groups, such as the elderly and
adolescents.
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Effectiveness of perampanel in real-world clinical
settings
While clinical trials constitute the gold standard
for assessing the efficacy and short-term tolerabil-
ity of any new medication, they do not provide
information on longer-term safety, nor can they
predict how well the drug will work in clinical
practice. Therefore, real-world experience is of
great importance because it complements clinical
data, provides valuable insight into how epilepsy
treatment impacts different patient populations,
and helps to inform on the use of newer AEDs.
Perampanel has been available since 2012 in
Europe and real-world experience with this agent
is now accumulating. Much of the data below
have been recently presented in preliminary form,
but some of the first results are now fully
published (16, 17). Study design and patient base-
line characteristics for these studies are presented
in Table 1. With the exception of the one multi-
center study from Germany and Austria
(N = 281) (17), most studies have included only
small patient populations (N = 9–74) (16, 18–27).
Studies varied in length, but most had observa-
tion periods of 6 months or more (Table 1).
Patients tended to have severe refractory epilepsy,
having failed between 1 and 17 previous AEDs
before starting perampanel, which was adminis-
tered at doses of 2–15 mg/day.
Efficacy and safety of perampanel
Real-world data from a wide range of clinical set-
tings and representing up to 3 years’ continuous
experience with perampanel have shown an
Table 1 Study design and baseline data for prospective and retrospective studies of perampanel in real-life clinical settings
Country N
Age, mean
(range)
Dose,
mean (range) Design
Duration of
observation,
months
Duration of
epilepsy, years,
mean (range)
Previous
AEDs, n Baseline AEDs
Germany and
Austria (17)
281 39 (12–84) 7.7 mg
(4–15 mg)
Cross-sectional,
observational
study across 9 centers
6* – – 1 AED, 16%; 2 AEDs, 43%; 3
AEDs, 22%, 4 AEDs, 18%
Germany (Kork) (16) 74 38.4 (15–71) 8.8 mg
(4–14 mg)
4 mg: 14%
6 mg: 18%
8 mg: 22%
10 mg: 11%
12 mg: 34%
14 mg: 1%
Prospective
observational study
6* – – 1 AED, 11%; 2 AEDs, 47%;
3 AEDs, 34%, 4 AEDs, 8%
Denmark (18) 22 32 (20–64) (2–8 mg)
2 mg: 1/22
4 mg: 9/22
6 mg: 6/22
8 mg: 6/22
– 8 mean
(range: 3–13)
17 (2–54) – 1–3 AEDs
Scotland (19) 22 48 median
(23–65)
Median 4 mg
(4–12 mg)
Prospective
observation study
6 – 1–15 schedules
(median 3
schedules)
1–4 AEDs (median 2)
Canada (20) 9 37.4 4 mg: 1/9
6 mg: 1/9
12 mg: 7/9
Prospective SAP 3 years – – 2 AEDs: 88.8%
3 AEDs: 11.2%
England, Bristol (21) 60 40 median
(18–77)
6 mg median
(2–12 mg)
Retrospective
observation study
14 24 (3–76) 5 median
(range: 2–12)
3 median (range 1–5)
England,
Cornwall (22)
24 (22–61) (2–6 mg) Retrospective
observation study
16 – 8 mean
(range: 1–12)
(range 1–3)
England, Leads (23) 39 – – Prospective
observation study
– – 9 median
(range: 5–11)
–
England,
Birmingham (24)
16 42 median
(24–59)
(4–12 mg) Retrospective audit 7–285 days 30 (7–53) 11 (range: 3–16) Range: 2–3
England,
Manchester (25)
30 30.5 median
(19–50)
8 mg median
(2–12 mg)
Retrospective
observation study
– – – –
Wales (26) 36 – – 3 epilepsy centers 134 days
(6–431 days)
22 5.8 mean 2.1 mean
Ireland (27) 20 31.3 median
(28–63)
– Retrospective
observation study
3–12 – 10 median
(range: 5–17)
–
AED, anti-epileptic drug; SAP, Special Access Programme.
*Patients had been on treatment for at least 6 months, and the assessment period for efficacy was 3 months.
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efficacy and safety profile that is consistent with
that demonstrated in the phase 3 studies and
their extension (11–14). Clinical response, defined
as a reduction of seizure frequency of at least
50%, occurred in up to 89% of patients,
although there was considerable variation [rang-
ing from 9% in Denmark to 89% (for secondar-
ily generalized seizures) in Cornwall, England],
which may relate to the perampanel doses admin-
istered and the small sample sizes in some studies
(Table 2). In the large, multicenter audit con-
ducted in Germany and Austria, response rates
were 46% in 281 patients receiving a mean per-
ampanel dosage of 7.7 mg/day (17). Similar
response rates of 50% were reported in another
German study, where 74 patients received peram-
Table 2 Efficacy and tolerability data for prospective and retrospective studies of perampanel in real-life clinical settings
Cohort Responder rate Seizure free Retention rate Adverse events
Germany and Austria (17) 50% 15% 60% All AEs: 52.0%
Somnolence: 24.6%
Dizziness: 19.6%
Ataxia: 3.9%
Aggression: 2.8%
Nausea: 2.5%
Irritability: 2.1%
Germany (Kork) (16) 34/74 (46%) 10/74 (14%) 52/74 (70%) All AEs: 40/74 (54%)
Somnolence: 31/74 (42%)
Dizziness: 13/74 (18%)
Ataxia, irritability, falls, cognitive slowing,
and depression in single cases
Denmark (18) 9% 2/22 (9.1%) 68% Fatigue: 8/22 (33.3%)
Aggressiveness: 5/22 (22.7%)
Dizziness: 4/22 (18.1%)
No AEs: 9/22 (40.9%)
Scotland (19) 4/22 (18.2%) 1/22 (4.5%) 24/41 (58.5%) All AEs: 15/22 (68.2%)
Depression: 3/22 (13.6%)
Weight gain: 3/22 (13.6%)
Irritability: 2/22 (9.0%)
Aggression: 1/22 (4.5%)
Paranoia: 1/22 (4.5%)
Canada (20) – 2/9 (22%) 8/9 (88.9%) Dizziness: 1/9
Falls/injury: 1/9
Weight loss: 1/9
Prolonged QTc interval: 1/9
England, Bristol (21) 16/60 (27%)
27% (SG)
27% (CP)
10/60 (17%) 75% All AEs: 37%
Dizziness: 27%
Unsteadiness: 17%
Behavioral disturbance: 8%
England, Cornwall (22) 89% (SG);
75% (CP)
2/24 (8.3%) 75% Unsteadiness: 6/24 (25%)
Dizziness: 4/24 (17%)
Behavior disturbances: 4/24 (17%)
England, Leeds (23) 50% (GTC) 45% (CP) 1/39 (2.6%) 27/39 (70%) Sedation: 46%
Dizziness: 18%
Unsteadiness: 15%
Headache: 10%
Anger/aggression: 10%
England, Birmingham (24) 3/16 (18.8%) 0% 7/16 (43.8%) Behavioral disturbance: 37%
Sedation: 18.8%
Dizziness: 18.8%
Unsteadiness: 12.5%
England, Manchester (25) 5/19 (26%) – 19/30 (63.3%) Dizziness: 8/30 (26.6%)
Sedation: 7/30 (23.3%)
Behavioral disturbance: 6/30 (20%)
Unsteadiness: 5/30 (16.7%)
Confusion/mental slowing: 4/30 (13.3%)
Depersonalization/abnormal thoughts: 3/30 (10%)
Wales (26) 66.7% – 75% All AEs: 16/36 (44%)
Ireland (27) 7/20 (35%) 0% 10/20 (50%) All AEs: 11/20 (55%)
Fatigue: 7/11
Mood/behavioral alteration: 6/11
Dizziness: 2/11
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panel at a mean dosage of 8.8 mg/day (16).
Across all real-life studies, up to 22% of patients
were seizure free (Table 2), with 14% of patients
being seizure free in the single-center German
study, and 15% being seizure free in the multi-
center study in Germany and Austria (16, 17).
Retention rates were relatively high across all
studies, ranging from 44% to 89% (Table 2),
with highest retention in patients receiving slow
titration (<2 mg every 2 weeks) (26).
Perampanel was well tolerated across all avail-
able observational studies, with approximately
37–68% of patients experiencing any adverse
events (Table 2). The most common adverse
events were somnolence and dizziness (Table 2)
as would be expected based on data from clinical
trials (11–14). Ataxia, behavior disturbances (ag-
gression, irritability), nausea, falls, unsteadiness,
cognitive slowing, and depression were also often
reported (Table 2). In the largest observational
study (from Austria and Germany), the probabil-
ity of adverse events did not clearly correlate with
perampanel dosage (17). In this study, tolerability
was better in patients receiving one or two
baseline AEDs than in those on more than two
AEDs (17). Psychiatric adverse events in this
study were in the range that would be expected in
these difficult-to-treat patients (17). Unexpected
serious adverse events (e.g., dermatological, cardi-
ologic, or laboratory findings) were not found
(16, 17).
Perampanel in different patient types
Perampanel and the elderly
Background – The management of epilepsy in the
elderly is complicated and challenging, particu-
larly as comorbidity and co-medication rates are
high (28, 29). Physiological changes associated
with aging, including impairment of hepatic and
renal function and age-related changes in receptor
numbers and function, affect the pharmacokinetic
and pharmacodynamic properties of agents and
increase the likelihood of side effects (28, 29). In
addition, high levels of polypharmacy increase
the chances of drug–drug interactions and associ-
ated toxicity (28). For these reasons, AED trials
in elderly patients are particularly challenging
and to date, only four randomized, double-blind,
comparative clinical trials in older patients have
been published, all of them in newly diagnosed
epilepsies (30–33). Other published reports of the
use of AEDs in elderly patients are scarce (34–
37). In general, there has been an increasing trend
away from the use of older AEDs in elderly
patients, for reasons including high levels of pro-
tein binding and unfavorable pharmacokinetics.
Salzburg prospective audit – In the Salzburg
prospective audit, the efficacy and tolerability of
perampanel in 20 elderly patients (7 female; mean
age 69.8 years, SD 7.8) and 65 younger patients
(39 female; mean age 36.8 years; SD 11.5) were
compared (38). Elderly patients had numerically
fewer seizures than younger patients in the last
month before baseline (mean 2.0 vs 8.4). The mean
number of concomitant medications was 1.74
(range 1–3) for elderly patients compared with
1.91 (range 0–4) for younger patients. Perampanel
dosages were 2–8 mg/day in elderly patients and
2–12 mg/day in younger patients. Over 57 months,
75% (15/20) elderly patients and 53.8% [35/65]
younger patients were still taking perampanel, and
35% (7/20) elderly patients were seizure free com-
pared with 13.8% (9/65) younger patients
(P = 0.009). In the elderly group, 5% (1/20) expe-
rienced seizure reduction 50–75%, and 20% (4/20)
experienced seizure reduction <50%, with data
missing for 3 patients at follow-up. This compared
with 3.1% (2/65) seizure reduction >75%; 15.4%
(10/65) seizure reduction 50–75%; and 56.9% (37/
65) seizure reduction <50% in younger patients.
Thirty-five percent (7/20) of elderly patients experi-
enced adverse events, compared with 55.4% (36/
65) of the younger patients (P = 0.563). Fatigue
(20%) and vertigo (15%) were the most common
adverse effects in the elderly group, while vertigo
(40%) and psychiatric effects (9.2%) were most
common in younger patients. Overall, the efficacy
and tolerability in elderly patients was good with
higher freedom-from-seizure rates observed in
elderly vs younger patients.
Although the clinical profile of perampanel
looks encouraging, prospective studies are needed
to explore the full potential of this drug in the
elderly. In addition, the adverse-event profile may
be found to differ in the elderly vs younger
patients, once data from real-world studies accu-
mulate or prospective studies are performed in
the elderly.
Practice points – In elderly patients, special atten-
tion has to be given to the high rate of comorbid
illnesses and co-medications. A careful look for
potential interactions and a critical review of the
current medication regimen in these patients can
help avoid potential adverse events. Based on our
clinical practice and personal experience, we rec-
ommend slower titration rates (e.g., <2 mg per
2 weeks). Also, patients may respond to lower
doses, and seizure control should be reassessed
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when they reach 4 mg perampanel, before
increasing the dose, if required.
Perampanel and adolescents
Efficacy – The efficacy of add-on treatment with
perampanel in adolescents has been evaluated in
three pivotal, double-blind, placebo-controlled,
phase 3 studies (studies 304, 305, and 306) (39).
In total, 145 patients aged 12–17 years with focal
seizures were randomized either to placebo or
perampanel 2, 4, 8, and 12 mg daily (Table 3).
The treatment period comprised a 6-week titra-
tion and 13-week maintenance period. The pri-
mary efficacy endpoint was the percent change in
seizure frequency over 28 days during double-
blind treatment phase vs baseline; secondary end-
points included 50% responder rate, and the
percent change in the frequency of complex par-
tial and secondarily generalized seizures over
28 days during the double-blind treatment phase
vs placebo. For pooled data from studies 304 and
305, the 50% responder rates in perampanel 8
and 12 mg/day groups were double that of the
placebo group. In study 306, perampanel doses 4
and 8 mg/day were most efficacious in terms of
50% responder rates compared with placebo
(note that the 12 mg dose was not included in
study 306) (Table 4).
In patients with complex partial seizures with
or without secondary generalization, all peram-
panel doses ≥4 mg/day resulted in marked mean
percent change from baseline compared with pla-
cebo: 42.9, 40.3, and 39.2 vs 4.4%, respec-
tively, for the 4, 8, and 12 mg doses vs placebo
(39).
Overall, 124 of 129 adolescent patients who
completed the ‘core’ phase 3 trials were enrolled
into an extension study (40) with an initial 16-
week blinded conversion period. Patients receiv-
ing placebo in the core studies were started on
perampanel 2 mg/day and titrated every 2 weeks
to the individualized maximum tolerated dose, up
to 12 mg/day. Patients receiving perampanel dur-
ing the core trials continued to receive the drug
on the blinded basis during the conversion per-
iod. At an interim cutoff date, 87 adolescent
patients reached ≥1 year of perampanel exposure,
and 44 reached ≥2 years (40). The results showed
improvement in seizure control following initia-
tion of perampanel for patients taking placebo in
the core studies and sustained improvement for
patients who received perampanel in a double-
blind study (40). The decrease in seizure fre-
quency was maintained up to 52 weeks (Tables 5
and 6).
Of interest, perampanel was most effective in
patients with secondarily generalized seizures.
These patients also had the highest 50% respon-
der rate during the entire treatment period. At
the interim cutoff, >50% reduction of seizure fre-
quency was observed in 59% patients with secon-
darily generalized seizures compared with 46% of
patients with complex partial seizures and 46% in
the overall patient population (≥1 year of
Table 3 Patient randomization in studies 304, 305, and 306 (39)
Category Randomized (n) Treated (n) Completed (n)*
Placebo 45 45 37
Perampanel 2 mg 21 21 20
Perampanel 4 mg 13 13 13
Perampanel 8 mg 45 44 41
Perampanel 12 mg 21 20 18
*Some patients did not complete the study either due to adverse events or
choice.
Table 4 50% responder rate in adolescents with focal seizures (39)
Study Placebo (%)
Perampanel (%)
2 mg/day 4 mg/day 8 mg/day 12 mg/day
304 and 305 22.2 DNS DNS 40.9 45.0
306 7.1 4.8 15.4 33.3 DNS
DNS, dose not studied in this trial.
Table 5 Median percent reduction in seizure frequency/28 days in adolescent
patients exposed to perampanel ≥1 year (40)
Weeks of
treatment
Overall, %
(n = 87)
CP and SG, %
(n = 77)
SG only, %
(n = 44)
1–13 34 39 53
14–26 46 47 64
27–39 55 52 73
40–52 47 45 65
CP, complex partial seizures; SG, secondarily generalized seizures.
Table 6 Median percent reduction in seizure frequency/28 days in adolescent
patients exposed to perampanel ≥2 years (40)
Weeks of
treatment
Overall, %
(n = 44)
CP and SG, %
(n = 37)
SG only, %
(n = 19)
1–13 23 39 60
14–26 32 47 65
27–39 57 57 71
40–52 50 50 65
53–65 54 62 88
66–78 67 68 80
79–91 58 77 85
92–104 61 62 90
CP, complex partial seizures; SG, secondarily generalized seizures.
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perampanel exposure). In the group exposed to
perampanel ≥2 years, the corresponding figures
comprised 74% patient with secondarily general-
ized seizures, 60% patient with complex partial
seizures, and 57% in the overall population (40).
Thus, the efficacy of adjunctive therapy with
perampanel in adolescents with focal seizures has
been demonstrated in phase 3 trials and extension
study. These results appear similar to those in
adult patients with focal epilepsy (39, 41).
Safety – The safety of perampanel in adolescent
patients with focal epilepsy has been demon-
strated in several studies (39–41). In phase 3 core
trials, the overall incidence of treatment-emergent
adverse events (TEAEs) was similar in placebo
group and all doses of perampanel (Table 7).
Discontinuation rate was the highest in placebo
group and in patients exposed to perampanel
12 mg/day (Table 5) (39). The most common
adverse events, occurring in more than 5% of
patients, included dizziness (20%), somnolence
(15%), aggression (8.2%), decreased appetite
(6%), and rhinitis (5%). Aggression rates were
higher in adolescent patients (18.2%) compared
with the overall population (4.5%) (41).
In the extension study, the overall incidence of
TEAEs was 88.4%, and the most commonly
observed adverse events included dizziness
(30.6%), somnolence (24%), nasopharyngitis
(19%), and aggression (18.2%) (40, 41). Of the
22 adolescent patients with treatment-emergent
aggression in the extension phase, 21 received
higher doses of perampanel (<8–12 mg), 17 were
male (77.3%), and the majority experience a sin-
gle episode of aggression (n = 16, 72.7%) (42).
In adolescent patients, the overall incidence of
TEAEs was similar between the placebo group
and all doses of perampanel (39). TEAEs of som-
nolence, nasopharyngitis, and aggression occurred
more frequently in adolescents than in the overall
population (41).
Practical recommendations – Although real-world
data for perampanel are accumulating, these data
are currently limited in adolescent patients.
Obtaining further data will be especially impor-
tant for this patient group because information
on drug safety and effectiveness in children and
adolescents from clinical trials is always less
prominent than that for adult patients. Based on
currently available clinical trial data, few recom-
mendations specific to adolescent patients can be
made. A similar efficacy of perampanel can be
expected in adolescents with focal epilepsy refrac-
tory to other AEDs. To avoid the potential
adverse events in adolescent patients, dose titra-
tion should be slow (every third to fourth week)
and individualized for each patient. As our
knowledge advances, real-world data will have a
key role in further clarifying practical recommen-
dations on the use of perampanel in adolescent
patients, particularly regarding behavioral
problems.
Patients taking concomitant enzyme-inducing anti-epileptic drugs
Enzyme-inducing (EI) AEDs may interfere with
the metabolism of perampanel and reduce the
serum concentrations of perampanel considerably
(14). An analysis of the phase 3 pharmacokinetic
and pharmacodynamic data showed that three EI
AEDs – carbamazepine, oxcarbazepine, and
phenytoin – increased perampanel clearance lead-
ing to a reduction of serum levels of up to 30%
(43).
Carbamazepine reduces mean exposure to per-
ampanel to approximately 70% of that observed
in the overall population (43, 44). It may there-
fore be expected to affect not only efficacy, but
also the rates of dose-related adverse events in
patients receiving perampanel. However, a recent
analysis of the pooled phase 3 data has indicated
little variation in the incidences of dizziness, som-
nolence, or headache in patients who were or
were not receiving the non-EI AEDs, valproic
acid, lamotrigine, or levetiracetam (45). Nonethe-
less, the efficacy of perampanel was reduced,
although still significantly superior to placebo, if
carbamazepine was among the AEDs to which
perampanel had been added (14). Physicians
should be aware that low serum concentrations
of perampanel may occur in some patients receiv-
ing perampanel in combination with EI AEDs; a
dosage increase in perampanel may be required
in these patients (14). However, variation in
response exists, with some patients on EI AEDs
and adjunctive perampanel showing a good
response, and others experiencing adverse events
at low dosages and serum concentrations of per-
ampanel in real-life clinical settings (16, 17). In
Table 7 Overall incidence of treatment-emergent adverse events (TEAEs) and
discontinuation rates for adolescents during the double-blind phase in studies
304, 305, and 306 (39)
Patient groups Incidence of TEAEs (%) Discontinuation (%)
Placebo (n = 45) 68.9 6.7
Perampanel 2 mg (n = 21) 71.4 0
Perampanel 4 mg (n = 13) 61.5 0
Perampanel 8 mg (n = 44) 75.0 2.3
Perampanel 12 mg (n = 20) 70.0 5.0
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the prospective observational study from Kork
(Germany), 43 patients (58%) were taking EI
AEDs. The responder rate in this group was 42%
(n = 18) compared with 48% (n = 15) in patients
taking non-EI AEDs; the difference was not
statistically significant (16).
Managing common side effects
To prevent the common adverse events with per-
ampanel, dosing should be individualized and a
slow-dose titration schedule initiated, particularly
in at risk individuals, such as the elderly and
adolescent patients. Adolescent patients, and
those with learning difficulties or dementia,
should be monitored closely during treatment ini-
tiation. In addition, psychiatric comorbidity and
family history of psychiatric disorders should be
considered when prescribing perampanel and
may suggest the need to consider slower dose
titration and close monitoring. The potential for
some adverse events, such as dizziness and som-
nolence during the day, may be minimized by
bedtime dosing of perampanel because pharma-
cokinetic data show that the peak plasma con-
centration of perampanel is reached at about
0.5–2.5 h after dosing (46). If dizziness or other
dose-related adverse events do occur, a dose
reduction should be considered. Note that it
takes approximately 2 weeks to reach steady
state levels of perampanel in plasma (down to
1 week for perampanel plus EI AEDs); titration
is therefore generally recommended every
2 weeks (or every 1 week in conjunction with an
EI-AED) (46). Therefore, if a patient is on per-
ampanel and an EI-AED, then titration every
2 weeks is slower than normal.
Dizziness
Background – Dizziness refers to ‘a disorienting
sensation such as faintness, light-headedness, or
unsteadiness’ (47). Without doubt dizziness is one
of the most often reported complaints in patients
taking central nervous active drugs, especially in
the elderly population. It occurs usually during
up-titration or under high doses, but decreases
after some time or with dose reduction. Due to
this dose dependency, dizziness is classified as
classic Type A adverse effect, which is often
accompanied by unsteadiness, vertigo, imbalance,
ataxia, diplopia, and tremor (48, 49). Dizziness is
one of the characteristic adverse events of first
generation AEDs (carbamazepine, phenytoin,
phenobarbital, primidone). In the Veterans
Administration Affair Monotherapy study, 44–
68% of the patients had treatment failures almost
exclusively due to and dizziness, sedation, and
coordination difficulties (50). In a meta-analysis
of randomized, placebo-controlled, add-on trials
of second-generation AEDs (gabapentin, lamot-
rigine, levetiracetam, oxcarbazepine, pregabalin,
tiagabine, topiramate, and zonisamide), any dose
was associated with an almost threefold increase
in risk of coordination difficulties (51). The risk
was highest for oxcarbazepine (RR 4.70, 95% CI
2.61–8.45), lamotrigine (3.50, 2.06–5.96), topira-
mate (3.26, 2.1–5.03), and pregabalin (3.14, 1.37–
7.19), whereas it was not elevated for gabapentin
and levetiracetam at any dose (51).
Perampanel data – In pooled data from the phase
3 studies using perampanel as adjunctive treat-
ment, dizziness, somnolence, and headache were
the most frequent adverse events. In patients
receiving perampanel, dizziness was reported in
16%, 32%, and 43% for 4, 8, and 12 mg, respec-
tively, vs 9% for placebo (14). Although dizziness
was mild in most patients, it was also the adverse
event most frequently necessitating treatment
withdrawal, which was 0.6% with 2 mg, 0.6%
with 4 mg, 2.1% with 8 mg, and 4.3% with
12 mg, compared with 0.9% with placebo (14).
In a meta-analysis including 1178 patients treated
with perampanel and 503 treated with placebo,
the risk ratio for dizziness was 2.86 (95% CI
2.16–3.79) for any dose (52). A similar frequency
of dizziness was also found in open real-world
studies, in which somnolence and dizziness were
the most commonly reported adverse event. In a
study from Germany and Austria, 52% of
patients experienced adverse events, the most
common of which were somnolence (24.6%),
dizziness (19.6%), ataxia (3.9%), aggression
(2.8%), nausea (2.5%), and irritability (2.1%)
(53). In the Salzburg prospective audit, 125
patients with drug-resistant epilepsy received per-
ampanel as adjunctive treatment and were
observed over more than 20 months. Dizziness
was the most common adverse event (32%), fol-
lowed by fatigue (12%), psychiatric symptoms
(7%), cognitive deficits (6%), speech problems
(5%), nausea (4%), and gait problems (4%).
Most adverse events were mild, and dizziness dis-
appeared when dose was reduced by 2 mg and
patients were instructed to take perampanel at
bedtime. By doing this, the peak of dose effect
with a Cmax of about 1 h was not experienced by
the patients during sleep. Also a slower titration
rate (<2 mg per 2 weeks) resulted in decreased
dizziness and increased tolerability, which was
also found in another real-world study (26).
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Management of patients with dizziness – As dizzi-
ness is a multifactorial symptom, an individual-
ized approach is necessary to minimize its
occurrence. Although dizziness is a classic Type
A adverse effect, which is clearly dose related,
there are also patient related factors, such as age,
comorbid polyneuropathy, structural brain
lesions, visual problems, or hypoacusis. In these
patients, a slower titration rate is mandatory
(e.g., <2 mg per 2 weeks). Special attention
should be drawn to the co-medication, which is
very common in the elderly population due to the
high comorbidity (28). Virtually any centrally
active drug, but also antihypertensives or diuret-
ics, may cause or aggravate dizziness. In patients
with drug-resistant epilepsy, the total drug load
has to be taken into consideration when dizziness
occurs. Sometimes a reduction of concomitant
drugs is necessary when up-titrating perampanel.
Due to the specific pharmacokinetic profile with
high Cmax after 0.5–2.5 h (46), it is advisable to
take the medication immediately before bedtime.
Behavioral change and aggression
Background – Aggression can be defined as an
apparent unprovoked assault, verbal or physical
or both, resulting from irritability, impulsivity,
anger, and hostility. These behavioral changes in
response to the addition of some AEDs are exac-
erbated by the high incidence of neurophysiologi-
cal and psychiatric comorbidities occurring
particularly in the drug-resistant epilepsy popula-
tion (54). The major neurotransmitter systems
implicated in the pathogenesis of aggression
include serotonin, glutamate, norepinephrine,
dopamine, and d-aminobutyric acid together with
their respective receptors (55). Levetiracetam
stands out as the AED most likely to produce or
worsen hostility and aggression across of a range
of epilepsy patient populations (56–63). Other
AEDs implicated in producing behavioral
changes include topiramate (64) and zonisamide
(62). Associated factors have included fast titra-
tion rates, previous aggression, a psychiatric his-
tory, a history of febrile seizures, and a family
history of psychiatric disorders (58, 64, 65). The
possibility of physical violence in this setting is
always a concern (57).
Perampanel data – Aggression is listed as a ‘com-
mon’ psychiatric disorder in the Fycompa [per-
ampanel] Summary of Product Characteristics
(66). Anger, aggression, and hostile behavior have
been reported in patients taking adjunctive per-
ampanel, particularly at higher dosage. Most
events were mild or moderate, and some patients
recovered spontaneously or with dosage adjust-
ment. However, thoughts of harming others,
physical assault or threatening behavior were
observed in <1% patients in clinical trials with
perampanel.
Serious psychiatric TEAEs – most commonly
aggression – were reported in 12/1480 (1.2%)
patients with partial-onset seizures receiving per-
ampanel in a pooled analysis of three phase 3
studies [vs 4 patients (0.9%) receiving placebo]
(12). Further analysis of TEAEs suggestive of
hostility or aggression showed that irritability
(4 mg, 4%; 8 mg, 7%; 12 mg, 12%; vs placebo,
3%) and aggression (4 mg, 1%; 8 mg, 2%;
12 mg 3%; vs placebo, 1%) were the most
common (14).
In the core phase 3 perampanel studies, 143
adolescent patients (aged 12–17 years) received at
least one dose of perampanel (n = 98 vs n = 45
placebo) (39). Aggression was reported as a
TEAE by eight adolescents (8%) in the peram-
panel group vs none randomized to placebo. In
the extension study, aggression occurred more
frequently as a TEAE in adolescents (18.5%)
than in adults (3.6%) (41). A randomized, dou-
ble-blind, placebo-controlled study of the short-
term effect of adjunctive perampanel (2–12 mg/
day) on cognition in adolescents (12–17 years)
with inadequately controlled partial-onset seizures
found that 15 patients (17.6%) taking peram-
panel experienced at least one adverse event relat-
ing to hostility or aggression (vs placebo, n = 2;
4.2%) (67). TEAEs were considered serious in
two of those patients on perampanel (daily dose
8 and 12 mg); however, both completed the study
and continued into the extension phase.
Glasgow perampanel audit – Seven of 41 patients
enrolled in the ongoing prospective audit of
adjunctive perampanel in patients with refractory
epilepsy (Western Infirmary Epilepsy Unit, Glas-
gow) withdrew due to neuropsychiatric side
effects (three depression, two irritability, one each
aggression, and paranoia) (19). Patients with
overt anger issues and major psychiatric problems
were specifically excluded from the audit. The
patient exhibiting aggression had focal refractory
epilepsy and was taking high-dose oxcarbazepine
and zonisamide when perampanel was introduced
in January 2013. The dose was titrated up to
8 mg nocte without problem until mid-June 2013,
when his general practitioner stopped perampanel
after the patient developed uncharacteristic
aggressive behavior. The problem rapidly
resolved spontaneously thereafter.
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Management of aggression with perampanel – Many
patients with epilepsy, particularly those taking
levetiracetam, self-report feelings of anger toward
others (68). The situation is made more compli-
cated by the high prevalence of comorbid psychi-
atric and behavioral disorders in patients with
refractory epilepsy (54). Conversely, no patients
with parkinsonism, neuropathic pain, multiple
sclerosis, or migraine receiving perampanel in
doses up to 8 mg daily in clinical trials reported
aggression or hostility (69). Arguably, from a
clinician’s perspective, it would seem appropriate
to consider avoiding use in patients with a history
of serious anger management issues and/or hos-
tile or aggressive behavior. In all other patients,
the possibility of irritability, impulsivity anger,
and aggression should be sensitively discussed
with the patient and their close family when pre-
scription of perampanel is being considered.
Some patients do not notice their own behavior
change, so family input is essential; providing a
contact number for patients and their family to
report any inappropriate behavior to their physi-
cian can be useful. All such problems should be
monitored while the perampanel dose is titrated
to the optimum amount for each individual
patient. Documentation of any personal or family
history of psychiatric disorders will alert the pre-
scriber to consider slower introduction of the
drug.
Particular care should be taken when prescrib-
ing perampanel for patients with learning disabil-
ity or dementia. Adolescents, too, are particularly
susceptible to developing behavioral side effects
with perampanel (41, 67), and hence, its introduc-
tion should be closely monitored in this popula-
tion. There is some evidence that alcohol may
exacerbate levels of anger in some patients; this
issue should be explored in patients reporting
behavioral problems with perampanel (66). To
the authors’ knowledge, there are no data to sug-
gest that behavioral problems with perampanel
are likely to be any worse in patients who were
already taking levetiracetam. Aggression and hos-
tility have the potential for serious medico-legal
implications, and so, accurate documentation in
the case notes and in the correspondence to the
patient’s general practitioner of any behavioral
problems should be an essential accompaniment
to each consultation, particularly if a problem
with impulsivity, anger, or aggression is reported.
These symptoms can be managed in many
patients without necessarily withdrawing the per-
ampanel. The patient and family are normally in
a good position to decide whether or not to
discontinue the drug should a behavioral problem
arise.
Falls, fatigue, and somnolence
Falls are among the more frequently reported
adverse events in the randomized controlled
phase 3 trials with adjunctive perampanel. In
these three pivotal trials (10–12), adverse drug
reactions occurring in more than 5% of patients
receiving perampanel 4–12 mg were dizziness
(16%, 32%, and 43% for 4, 8, and 12 mg,
respectively, vs 9% for placebo), somnolence
(9%, 16%, and 18% vs 7%), fatigue (8%, 8%,
and 12% vs 5%), irritability (4%, 7%, and 12%
vs 3%), nausea (3%, 6%, and 8% vs 5%), and
falls (2%, 5%, and 10% vs 3%) (14). Falls were
more frequent with perampanel 8 or 12 mg than
with placebo, although only one fall was consid-
ered a serious TEAE (14). Accordingly, the
potential for increased risks of falls (along with
aggression and suicidal ideation) is noted in the
European and US licenses (14).
Falls may occur more frequently in individuals
older than 65 years than in younger patients.
Although overall adverse-event rates were similar
in perampanel-treated patients aged ≥65 years
(n = 20) and those aged ≥18 to <65 years
(n = 920) in a subanalysis of pooled phase 3 data
by age, some individual adverse events were
reported more frequently in patients aged
≥65 years. These included dizziness (45.0% vs
28.6% for placebo), fatigue (25.0% vs 8.7%), and
falls (25.0% vs 4.9%) (53). While these data rep-
resent a relatively small elderly population, the
increased likelihood of these adverse events may
warrant slower up-titration of the perampanel
dose in patients aged ≥65 years (53). The ‘warn-
ings and precautions’ section of the prescribing
information also recommends monitoring for gait
disturbance, as well as falls and injuries. It has
been suggested that the risk of falls may be asso-
ciated with dizziness and somnolence (53).
As mentioned above, fatigue and somnolence
together with dizziness belong to the most fre-
quent adverse events reported under adjunctive
perampanel in the pivotal trials (10–12, 14, 70).
This is supported by a meta-analysis of the phase
2 and phase 3 data, which has indicated that,
compared with placebo, perampanel 8 and 12 mg
were associated with greater incidences of somno-
lence (significant at 8 mg only: 8 mg, risk ratio
2.17, 95% CI 1.19–3.93; 12 mg, risk ratio 3.11,
95% CI 0.81–11.97). Other adverse drug reac-
tions reported in ≥5% of patients treated with
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perampanel 4–12 mg in the phase 3 trials were
fatigue, irritability, nausea, and falls (14, 53).
The dose-dependent incidences of fatigue and
somnolence are shown in Table 8. This was con-
firmed by the open-label, follow-up study after
the pivotal trials (13, 16, 17, 53). In the phase 3
extension study that comprised 1216 patients,
fatigue and somnolence were among the five
adverse events that were reported in ≥10% of
patients. Somnolence was reported in 21.2% and
fatigue in 13.1%. Other side effects than somno-
lence and fatigue, namely dizziness and irritabil-
ity, were responsible for discontinuations of
perampanel in 1% or more of the patients (13).
The increased incidence of somnolence and
fatigue in clinical trials is reflected in real-world
data. In the single-center, post-launch observa-
tional trial in 84 patients treated at the Kork Epi-
lepsy Centre (16), somnolence and fatigue
(summarized as somnolence) were reported in
42% of patients. However, only one patient dis-
continued perampanel due to somnolence. Other
leading side effects were dizziness (n = 13, 18%),
followed by ataxia, irritability, falls, cognitive
slowing, and depression in single cases (16).
Physicians found that somnolence and dizziness
generally could be prevented or reduced with the
strategy of using perampanel at bedtime (16).
Furthermore, the multicenter survey of nine epi-
lepsy centers in Germany and Austria (17)
revealed somnolence in 24.6% of patients.
Conclusions
Perampanel has shown high rates of efficacy and
good tolerability in real-world settings, with most
adverse events being mild and no severe adverse
events reported to date. The safety profile of per-
ampanel in the elderly and adolescents is similar
to that for adults. The most frequently reported
adverse events are dizziness, fatigue, and somno-
lence. The risk of these adverse events can be
reduced by dosing of perampanel at bedtime.
Adverse events can also be managed with slow-
dose titration and dose adjustments.
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